{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:53:45Z","timestamp":1788497625369,"version":"build-2803163510"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T00:00:00Z","timestamp":1545782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0204099","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T18:34:37Z","timestamp":1545849277000},"page":"e0204099","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials"],"prefix":"10.1371","volume":"13","author":[{"given":"Marilyn","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3276-9925","authenticated-orcid":true,"given":"Charles","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elna","family":"van der Ryst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette M.","family":"Whitcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Westby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,12,26]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006866","article-title":"HIV: cell binding and entry","volume":"2","author":"CB Wilen","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jmv.24036","article-title":"HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy","volume":"87","author":"I Bon","year":"2015","journal-title":"J Med Virol"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"e102857","DOI":"10.1371\/journal.pone.0102857","article-title":"HIV-1 tropism dynamics and phylogenetic analysis from longitudinal ultra-deep sequencing data of CCR5- and CXCR4-using variants","volume":"9","author":"MM Sede","year":"2014","journal-title":"PloS One"},{"issue":"6664","key":"ref4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/34571","article-title":"A new classification for HIV-1","volume":"391","author":"EA Berger","year":"1998","journal-title":"Nature"},{"issue":"21","key":"ref5","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1128\/JVI.74.21.10229-10235.2000","article-title":"Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies","volume":"74","author":"A Singh","year":"2000","journal-title":"J Virol"},{"issue":"16","key":"ref6","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1097\/QAD.0b013e32833e6cfb","article-title":"Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies","volume":"24","author":"RA McGovern","year":"2010","journal-title":"AIDS"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2012.11.002","article-title":"Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naive HIV patients screened for Study A4001078","volume":"97","author":"S Portsmouth","year":"2013","journal-title":"Antiviral Res"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jac\/dkq458","article-title":"Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment","volume":"66","author":"L Vandekerckhove","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"ref9","doi-asserted-by":"crossref","first-page":"O7","DOI":"10.1186\/1758-2652-13-S4-O7","article-title":"Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing","volume":"13","author":"L Vandekerckhove","year":"2010","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"P Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1073\/pnas.090576697","article-title":"A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5","volume":"97","author":"T Dragic","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/mol.107.042101","article-title":"Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists","volume":"73","author":"R Kondru","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.virol.2006.01.018","article-title":"Interaction of small molecule inhibitors of HIV-1 entry with CCR5","volume":"349","author":"C Seibert","year":"2006","journal-title":"Virology"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1021\/jm100978n","article-title":"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)","volume":"54","author":"PA Stupple","year":"2011","journal-title":"J Med Chem"},{"issue":"6152","key":"ref15","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 chemokine receptor HIV entry inhibitor maraviroc complex","volume":"341","author":"Q Tan","year":"2013","journal-title":"Science"},{"issue":"38","key":"ref16","doi-asserted-by":"crossref","first-page":"33409","DOI":"10.1074\/jbc.M111.279596","article-title":"Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5)","volume":"286","author":"J Garcia-Perez","year":"2011","journal-title":"J Biol Chem"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jmb.2008.06.041","article-title":"Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into mechanism of allosteric inhibition","volume":"381","author":"K Maeda","year":"2008","journal-title":"J Mol Biol"},{"issue":"16","key":"ref18","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1128\/JVI.78.16.8654-8662.2004","article-title":"Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine\/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro","volume":"78","author":"K Maeda","year":"2004","journal-title":"J Virol"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","article-title":"Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry","volume":"81","author":"M Westby","year":"2007","journal-title":"J Virol"},{"issue":"22","key":"ref20","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1128\/JVI.01384-15","article-title":"Characterizing the diverse mutational pathways associated with R5-tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor","volume":"89","author":"X Jiang","year":"2015","journal-title":"J Virol"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir","volume":"80","author":"M Westby","year":"2006","journal-title":"J Virol"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"e1001022","DOI":"10.1371\/journal.pcbi.1001022","article-title":"The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time: an ultra-deep approach","volume":"6","author":"J Archer","year":"2010","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"e1002106","DOI":"10.1371\/journal.ppat.1002106","article-title":"Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing","volume":"7","author":"EM Bunnik","year":"2011","journal-title":"PLoS Pathog"},{"issue":"14","key":"ref24","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1128\/JVI.78.14.7565-7574.2004","article-title":"Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching","volume":"78","author":"C Pastore","year":"2004","journal-title":"J Virol"},{"issue":"14","key":"ref25","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","article-title":"for the MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection","volume":"359","author":"G F\u00e4tkenheuer","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"ref26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"for the MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"RM Gulick","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/COH.0b013e3280142007","article-title":"Resistance to CCR5 antagonists","volume":"2","author":"M. Westby","year":"2007","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3851\/IMP1759","article-title":"Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients","volume":"16","author":"JM Schapiro","year":"2011","journal-title":"Antivir Ther"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00002030-199805000-00005","article-title":"Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice","volume":"12","author":"NA Roberts","year":"1998","journal-title":"AIDS"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1128\/AAC.00853-06","article-title":"Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism","volume":"51","author":"JM Whitcomb","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref31","first-page":"94","article-title":"An enhanced-sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies","volume":"3","author":"JD Reeves","year":"2009","journal-title":"J Viral Entry"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"DA Cooper","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/648090","article-title":"AIDS Clinical Trials Group A5211 Team. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211","volume":"200","author":"Z Su","year":"2009","journal-title":"J Infect Dis"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0b013e31827b51b5","article-title":"Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study","volume":"62","author":"A Mills","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"ref35","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/QAD.0000000000001058","article-title":"Once-daily maraviroc versus tenofovir\/emtricitabine each combined with darunavir\/ritonavir for initial HIV-1 treatment","volume":"30","author":"HJ Stellbrink","year":"2016","journal-title":"AIDS"},{"key":"ref36","article-title":"Pharmacokinetics, safety, and efficacy of maraviroc in treatment-experienced pediatric patients infected with CCR5-tropic HIV-1","author":"C Giaquinto","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/QAD.0b013e32832b4399","article-title":"Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing","volume":"23","author":"J Archer","year":"2009","journal-title":"AIDS"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jiq030","article-title":"Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients","volume":"203","author":"LC Swenson","year":"2011","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"ref39","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/1479-5876-9-S1-S6","article-title":"Selective transmission of R5 HIV-1 variants: where is the gatekeeper?","volume":"9","author":"J-C Grivel","year":"2011","journal-title":"J Transl Med"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/088922204322749567","article-title":"The CCR5 and CXCR4 coreceptors: central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection","volume":"20","author":"JP Moore","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1073\/pnas.96.9.5215","article-title":"Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages","volume":"96","author":"B Lee","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3934\/mbe.2011.8.605","article-title":"Persistence and emergence of X4 virus in HIV infection","volume":"8","author":"AD Weinberger","year":"2011","journal-title":"Math Biosci Eng"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/JVI.69.3.1810-1818.1995","article-title":"Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing\/SI phenotypically mixed human immunodeficiency virus population","volume":"69","author":"M Cornelissen","year":"1995","journal-title":"J Virol"},{"issue":"Suppl 1","key":"ref44","first-page":"S57","article-title":"Interactions between HIV and the host immune system in the pathogenesis of AIDS","volume":"4","author":"M Tersmette","year":"1990","journal-title":"AIDS"},{"issue":"9","key":"ref45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-118-9-199305010-00004","article-title":"Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS","volume":"118","author":"M Koot","year":"1993","journal-title":"Ann Intern Med"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1086\/314539","article-title":"Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis","volume":"179","author":"M Koot","year":"1999","journal-title":"J Infect Dis"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"a007443","DOI":"10.1101\/cshperspect.a007443","article-title":"HIV-1 pathogenesis: the virus","volume":"2","author":"R Swanstrom","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"ref48","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/QAD.0000000000000131","article-title":"Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings","volume":"28","author":"DA Cooper","year":"2014","journal-title":"AIDS"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1742-4690-10-43","article-title":"A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations","volume":"10","author":"M Roche","year":"2013","journal-title":"Retrovirology"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1128\/AAC.01057-08","article-title":"CCR100136 Study Team. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope","volume":"53","author":"KM Kitrinos","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"ref51","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1128\/JVI.00374-10","article-title":"HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells","volume":"84","author":"JM Pfaff","year":"2010","journal-title":"J Virol"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2006.11.004","article-title":"HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry","volume":"361","author":"P Pugach","year":"2007","journal-title":"Virology"},{"issue":"9","key":"ref53","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1128\/JVI.00106-11","article-title":"HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism","volume":"85","author":"M Roche","year":"2011","journal-title":"J Virol"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1179\/1528433614Z.0000000002","article-title":"The maraviroc expanded access program: safety and efficacy data from an open-label study","volume":"16","author":"A Lazzarin","year":"2015","journal-title":"HIV Clin Trials"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/ar3685","article-title":"Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial","volume":"14","author":"DL Fleishaker","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"ref56","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.104.008565","article-title":"The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor","volume":"67","author":"C Watson","year":"2005","journal-title":"Mol Pharmacol"},{"key":"ref57","article-title":"Analysis of clinical HIV-1 strains with resistance to maraviroc reveals strain-specific resistance mutations, variable degrees of resistance, and minimal cross-resistance to other CCR5 antagonists","author":"J Flynn","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"24","key":"ref58","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1093\/nar\/25.24.4876","article-title":"The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools","volume":"25","author":"JD Thompson","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"ref59","article-title":"Inferring evolutionary trees with PAUP","author":"JC Wilgenbusch","year":"2003","journal-title":"Curr Protoc Bioinformatics"},{"issue":"4","key":"ref60","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1558-5646.1985.tb00420.x","article-title":"Confidence limits on phylogenies: an approach using the bootstrap","volume":"39","author":"J. Felsenstein","year":"1985","journal-title":"Evolution"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0204099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T04:02:04Z","timestamp":1605844924000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0204099"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,26]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0204099","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,26]]}}}